Business Wire

BAE-SYSTEMS

10.12.2020 15:02:11 CET | Business Wire | Press release

Share
BAE Systems Helps Ireland Lead the Way With First Plug-In Electric Hybrid Propulsion Systems on Public Buses

BAE Systems, a world leader in electric propulsion , has delivered the first plug-in capable electric hybrid propulsion systems to Alexander Dennis Limited who are supplying new buses to Ireland. The Series-ER (Electric Range) systems will power Ireland’s fleet of up to 600 Enviro400ER hybrid buses. BAE Systems has supplied systems for the first 100 buses and will supply an additional 180 systems for buses next year.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201210005589/en/

The Series-ER system builds on the company’s more than 20 years of innovation and proven technology and powers more than 13,000 buses around the world. That technology is on buses in service throughout Europe, including cities such as Brighton, London, Namur, and Paris. The Irish buses are the first in the world to benefit from the company’s new plug-in technology.

This means that as well as using the efficient onboard generator to charge itself while the bus is on the move, the buses can now also plug into the grid for power, giving operators another way to recharge their buses.

The Series-ER system enables buses to run for up to five kilometers (three miles) at a time with the engine turned off. This capability provides towns and cities with a new opportunity to improve air quality. The buses will use up to 35 percent less fuel when compared to a conventional bus.

“Clean transportation technology in our cities is critical to reach a zero emission future,” said Ian Wilson, director of business development for Power & Propulsion Solutions at BAE Systems. “Our system will help Ireland take the next step towards full electrification and improve the air quality where people live, work and visit.”

“The Alexander Dennis Enviro400ER is ideally suited for flexible operating needs including zero-emission running at air pollution hotspots,” said Paul Davies president and managing director at ADL. “With the ability to externally charge the batteries, the use of on-board power generation can be further reduced. This new generation of double deck buses for Ireland once again demonstrates that with ADL’s focus on innovation, we are building the buses our cities need to solve their transport challenges.”

The bus propulsion system includes a highly efficient electric motor and generator, an enhanced battery, and smart electronic controls to create a clean form of electric drive propulsion for the buses. It allows operators to take advantage of green grid power, and sets them up for full electric operation in the future. Operators can now use the grid for power – much like an all-electric bus – and add more battery capacity to increase their engine off time. In many instances this will mean an entire route can operate on grid power when the necessary charging infrastructure is in place.

BAE Systems develops and services its technology at its facilities in Endicott, New York, and Rochester, UK.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye